Multicentre open-label phase 3 study evaluates ripasudil-brimonidine fixed-dose combination in glaucoma and ocular hypertension, highlighting intraocular pressure-lowering efficacy.
To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT).
No takes yet. Share an insight, caveat, or question.
Tanihara et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: